EMA/501355/2020

European Medicines Agency decision

P/0388/2020

of 29 September 2020

on the acceptance of a modification of an agreed paediatric investigation plan for eculizumab (Soliris) (EMEA-000876-PIP05-15-M04) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0388/2020

of 29 September 2020

on the acceptance of a modification of an agreed paediatric investigation plan for eculizumab (Soliris) (EMEA-000876-PIP05-15-M04) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/0046/2016 issued on 26 February 2016, the decision P/0185/2016 issued on 15 July 2016, the decision P/0323/2017 issued on 31 October 2017 and the decision P/0200/2018 issued on 19 July 2018.

Having regard to the application submitted by Alexion Europe SAS 5 June 2020 on 5 June 2020 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 4 September 2020, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for eculizumab (Soliris), concentrate for solution for infusion, intravenous use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision covers all conditions, indications, pharmaceutical forms, routes of administration, measures, timelines, waivers and deferrals, as agreed in the decision P/224/2010 issued on issued on 29 October 2010, including subsequent modifications thereof.

Article 3

This decision is addressed to Alexion Europe SAS, 103-105 rue Anatole France, 92300 - Levallois-Perret, France.

EMA/PDCO/330727/2020
Amsterdam, 4 September 2020

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-000876-PIP05-15-M04

Scope of the application

Active substance(s):

Eculizumab

Invented name:

Soliris

Condition(s):

Treatment of myasthenia gravis

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Concentrate for solution for infusion

Route(s) of administration:

Intravenous use

Name/corporate name of the PIP applicant:

Alexion Europe SAS

Information about the authorised medicinal product:

See Annex II

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Alexion Europe SAS submitted to the European Medicines Agency on 5 June 2020 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0046/2016 issued on 26 February 2016, the decision P/0185/2016 issued on 15 July 2016, the

decision P/0323/2017 issued on 31 October 2017 and the decision P/0200/2018 issued on 19 July 2018.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 6 July 2020.

Scope of the modification

Some measures of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition

Treatment of myasthenia gravis

The waiver applies to:

- the paediatric population from birth to less than 6 years of age;
- concentrate for solution for infusion, intravenous use;
- on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset(s).

2. Paediatric investigation plan

2.1. Condition

Treatment of myasthenia gravis

2.1.1. Indication(s) targeted by the PIP

Treatment of refractory acetylcholine receptor antibody (AChR-Ab) - positive generalised myasthenia gravis

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 6 to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Concentrate for solution for infusion

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	0	Not applicable
Non-clinical studies	0	Not applicable
Clinical studies	1	**Study 1** Open-label, multi-centre study to evaluate pharmacokinetics, safety and effect of eculizumab in paediatric patients from 6 to less than 18 years of age with refractory AChR-Ab positive generalized myasthenia gravis and to confirm the selected paediatric dosing in the modelling and simulation study (ECU-MG-303)

Extrapolation, modelling and simulation studies	2	**Study 2** Modelling and simulation study to evaluate the use and support dosing regimen of eculizumab in paediatric patients from 6 to less than 18 years of age with refractory AChR-Ab positive generalized myasthenia gravis **Study 3** Extrapolation study to evaluate efficacy, pharmacokinetics/pharmacodynamic and safety of eculizumab in paediatric patients from 6 to less than 18 years of age with AChR-Ab positive generalized myasthenia gravis
Other studies	0	Not applicable
Other measures	0	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By March 2022
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

Treatment of Paroxysmal Nocturnal Haemoglobinuria

Authorised indication(s):

Soliris is indicated in adults and children for the treatment of patients with paroxysmal nocturnal haemoglobinuria (PNH). Evidence of clinical benefit is demonstrated in patients with haemolysis with clinical symptom(s) indicative of high disease activity, regardless of transfusion history.

Treatment of Atypical Haemolytic Uraemic Syndrome

Authorised indication(s):

Soliris is indicated in adults and children for the treatment of patients with atypical haemolytic uremic syndrome (aHUS).

Treatment of myasthenia gravis

Authorised indication(s):

Soliris is indicated in adults for the treatment of refractory generalized myasthenia gravis (gMG) in patients who are anti-acetylcholine receptor (AChR) antibody-positive.

Treatment of neuromyelitis optica spectrum disorders

Authorised indication(s):

Soliris is indicated in adults for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in patients who are anti-aquaporin-4 (AQP4) antibody-positive with a relapsing course of the disease.

Authorised pharmaceutical form(s):

Concentrate for solution for infusion

Authorised route(s) of administration:

Intravenous use